187 related articles for article (PubMed ID: 34748702)
1. GMP Compliant Synthesis of [
van der Hoek S; Antunes IF; Attia KA; Jacquet O; Heeres A; Bulthuis M; Zijlma R; Boersma HH; van Goor H; Visser TJ; Heerspink HJL; Elsinga PH; Stevens J
J Med Chem; 2021 Nov; 64(22):16641-16649. PubMed ID: 34748702
[TBL] [Abstract][Full Text] [Related]
2. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
[TBL] [Abstract][Full Text] [Related]
3. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
4. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer's disease- diabetes type 2 linkage via an enzoinformatics study.
Rizvi SM; Shakil S; Biswas D; Shakil S; Shaikh S; Bagga P; Kamal MA
CNS Neurol Disord Drug Targets; 2014 Apr; 13(3):447-51. PubMed ID: 24059302
[TBL] [Abstract][Full Text] [Related]
5. Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754).
Lin R; Hoerr DC; Weaner LE; Salter R
J Labelled Comp Radiopharm; 2017 Nov; 60(13):616-623. PubMed ID: 28833358
[TBL] [Abstract][Full Text] [Related]
6.
López-Picón FR; Kirjavainen AK; Forsback S; Takkinen JS; Peters D; Haaparanta-Solin M; Solin O
Theranostics; 2019; 9(1):11-19. PubMed ID: 30662550
[TBL] [Abstract][Full Text] [Related]
7. One-step
Zhao X; Lv G; Li K; Peng Y; Liu Q; Qiu L; Lin J
Nucl Med Biol; 2020; 82-83():72-79. PubMed ID: 32109829
[TBL] [Abstract][Full Text] [Related]
8. The development of an automated and GMP compliant FASTlab™ Synthesis of [(18) F]GE-180; a radiotracer for imaging translocator protein (TSPO).
Wickstrøm T; Clarke A; Gausemel I; Horn E; Jørgensen K; Khan I; Mantzilas D; Rajanayagam T; in 't Veld DJ; Trigg W
J Labelled Comp Radiopharm; 2014 Jan; 57(1):42-8. PubMed ID: 24448744
[TBL] [Abstract][Full Text] [Related]
9. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the sodium-glucose co-transporter SGLT2 by canagliflozin ameliorates diet-induced obesity by increasing intra-adipose sympathetic innervation.
Yang X; Liu Q; Li Y; Ding Y; Zhao Y; Tang Q; Wu T; Chen L; Pu S; Cheng S; Zhang J; Zhang Z; Huang Y; Li R; Zhao Y; Zou M; Shi X; Jiang W; Wang R; He J
Br J Pharmacol; 2021 Apr; 178(8):1756-1771. PubMed ID: 33480065
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
13. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of [¹¹C]PBR06 and [¹⁸F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO).
Wang M; Gao M; Miller KD; Zheng QH
Steroids; 2011 Nov; 76(12):1331-40. PubMed ID: 21756927
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Said S; Hernandez GT
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
[TBL] [Abstract][Full Text] [Related]
16. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.
Yao CH; Lin KJ; Weng CC; Hsiao IT; Ting YS; Yen TC; Jan TR; Skovronsky D; Kung MP; Wey SP
Appl Radiat Isot; 2010 Dec; 68(12):2293-7. PubMed ID: 20638295
[TBL] [Abstract][Full Text] [Related]
17. High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection.
Umino H; Hasegawa K; Minakuchi H; Muraoka H; Kawaguchi T; Kanda T; Tokuyama H; Wakino S; Itoh H
Sci Rep; 2018 May; 8(1):6791. PubMed ID: 29717156
[TBL] [Abstract][Full Text] [Related]
18. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Mikhail N
South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
[TBL] [Abstract][Full Text] [Related]
19. 18F-labeling and evaluation of novel MDL 100907 derivatives as potential 5-HT2A antagonists for molecular imaging.
Debus F; Herth MM; Piel M; Buchholz HG; Bausbacher N; Kramer V; Lüddens H; Rösch F
Nucl Med Biol; 2010 May; 37(4):487-95. PubMed ID: 20447561
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule.
Ghezzi C; Yu AS; Hirayama BA; Kepe V; Liu J; Scafoglio C; Powell DR; Huang SC; Satyamurthy N; Barrio JR; Wright EM
J Am Soc Nephrol; 2017 Mar; 28(3):802-810. PubMed ID: 27620988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
